medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2007, Number 1

<< Back Next >>

An Med Asoc Med Hosp ABC 2007; 52 (1)

Effect of sulphonylureas use on the ST segment deviation of the electrocardiograms from patients with acute myocardial infarction

Fernández CE, Olvera OK, Ordaz RE, Juárez VMA

Language: Spanish
References: 19
Page: 5-13
PDF size: 116.90 Kb.


ABSTRACT

Sulfonylureas produce their hypoglycemic effect via blockage certain potassium channels found in the pancreas, similar channels are present in many other organs. Sulfonylureas are able to attenuate the electrocardiographic changes during an acute myocardial infarction and in previous research a greater mortality among diabetics who use these drugs is described. Methods: The files of every diabetic patient with acute myocardial infarction diagnosis were retrospectively analyzed. Electrocardiograms (ST segment) between groups taking sulfonylureas or not were compared, measuring ST segment magnitude deviation and performing the statistical analysis of such variables. Results: 65 diabetic patients were included, 22 without sulfonylureas intake and 44 being treated with these drugs (31 with glibenclamide and 13 with other sulfonylureas). Demographic data were similar between groups. Among patients with creatine phosphokinase levels between 601 and 2000 mg/dL the average ST segment deviation in the sulfonylureas group was significantly lower than in the non-sulfonylureas group (2.44 ± 1.29 vs. 1.29 ± 0.58 mm, p = 0.029 ). This effect was more evident with glibenclamide (2.44 ± 1.29 vs. 1.18 ± 0.50 mm, p = 0.020). There were no significant differences in the intrahospitalary mortality between the groups. Conclusions: Sulfonylureas (mainly glibenclamide) can significantly diminish ST segment elevation during an acute myocardial infarction. This must be considered when diagnostic approach is done in every patient with chest pain.


REFERENCES

  1. Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med 1942; 441: 21-22.

  2. Patlak M. Combating diabetes. The FASEB Journal. 2002; 16: 1853E-1853E.

  3. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53 (suppl 3): S156-S164.

  4. Farouque HM, Worthley SG, Meredith IT, Skyrme-Jones RA, Zhang MJ. Effect of ATP-sensitive potassium channel inhibition on resting coronary vascular responses in humans. Circ Res 2002; 90: 231–236.

  5. Meier JJ, Gallwitz B, Schmidt WE, Mügge A, Nauck MA. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12.

  6. Andreotti F. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med 1996; 334: 7-12.

  7. Meinert CL. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19: 789-783.

  8. Garratt KN et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplastyfor acute myocardial infarction. J Am Col Cardiol 1999; 33: 119-124.

  9. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.

  10. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: A population-based cohort study. CMAJ 2006; 174 (2): 169-174.

  11. Reffelmann T, Klues HG, Hanrath P, Schwarz ER. Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease. Heart 2002; 87: 54–60.

  12. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90 (1): 531-537.

  13. Huizar JF, González LA, Alderman J, Smith HS. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. JACC 2003; 42 (6): 1017-1021.

  14. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90 (1): 501-506.

  15. Preacher KJ. Calculation for the chi-square test: An interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. Disponible en: http://www.quantpsy.org. (2001, April)

  16. Preacher KJ, Briggs NE. Calculation for Fisher’s exact test: An interactive calculation tool for Fisher’s exact probability test for 2 x 2 tables [Computer software]. Disponible en: http://www.quantpsy.org. (2001, May)

  17. Kubota I, Yamaki M, Shibata T. Role of ATP-sensitive potassium channel on ECG ST-segment elevation during a bout of myocardial ischemia. Circulation 1993; 88: 1845-1851.

  18. Hambrock A, Löffler-Walz C, Russ U, Lange U, Quast U. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: Differences in the coupling to Kir6.x subtypes. Mol Pharmacol 2001; 60: 190–199.

  19. Preacher KJ, Coffman DL. Computing power and minimum sample size for RMSEA [Computer software]. Disponible en: http://www.quantpsy.org/ (2006, May).




2020     |     www.medigraphic.com